88 Investor presentation First six months of 2023 Main part of the Explorer 8 trial w HA or HB without inhibitors has b Explorer 8 trial design Previously OnD treatment R 1:2 Prophylaxis treatment (continued from phase 2) Prophylaxis treatment (additional patients) 1 Maintained OnD treatment 2 Concizumab PPX, QD 3 Concizumab PPX, QD 4 Concizumab PPX, QD Main part 24 weeks Exten conc prop Exten Up to 1 Key inclusion criteria: • Aged ≥12 years with haemophilia A or haemophilia B, patients mainly from phase 2 Objective: • Assess the efficacy of Concizumab PPX vs no PPX (OnD treatment) in reducing number of bleeding episodes Endpoints: • Number of bleeding ep (spontaneo 1 Restart refers to the start of treatment with the new concizumab dosing regimen, which was implemented after the treatment pa HA: Haemophilia A; HB: Haemophilia B; HwI: Haemophilia with inhibitors; Prophylaxis: PPX; OnD: On-demand, QD: Once-daily
Download PDF file